Histological Evaluation of the Effect of Clopidogrel (Plavix) on the Brain, Liver, and Kidney: Histopathology Study
Main Article Content
Abstract
Clopidogrel is a prodrug that is absorbed in the intestines and 85% of it is metabolized in the liver, while 15% is the active part of the drug as it works to inhibit platelet aggregation and thus not forming a blood clot. The current study aims to evaluate the histological effect of Clopidogrel on the tissues of the, brain, liver and kidney. Experiment design: The experiment included fifteen albino rats divided randomly into three groups and each group included five animals . The first group was considered the control group. It was received tap water and natural food. As for the second group, the animals were received 15 mg/kg of Clopidogrel once a day with water and food, while the animals of the third group were received 20 mg/kg of Clopidogrel once a day with water and food. The experiment lasted for a month. After the end of the experiment, the animals were anesthetized, and the organs were surgically obtained, and the organs were placed in a 10% formalin solution, and then the tissue preparation techniques were applied to them. Results: The results of the study showed that a drug had several effects in tissues, including atrophy, caseous necrosis, apoptosis of some cells, foamaus appearance, inflammation, and degradation of other cells.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Yan-Jiao Zhang, et al,(2017). Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives. Int. J. Environ. Res. Public Health , 14, 301.
II. Kuszynski, Dawn S; and Lauve ,D. Adam ,(2022). Pleiotropic efects of clopidogrel. Purinergic Signalling ,18:253–265.
III. Taubert, D.; von Beckerath, N.; Grimberg, G.; et al. (2006). Impact of P-glycoprotein on clopidogrel absorption. Clin. Pharmacol. Ther, 80, 486–501.
IV. Mafrand J-P (2012) The story of clopidogrel and its predecessor, ticlopidine: could these major antiplatelet and antithrombotic drugs be discovered and developed today? C R Chim 15:737– 743.
V. Coukell AJ, Markham A (1997) Clopidogrel. Drugs 54:745–50.
VI. Price, M.J.; Angiolillo, D.J.; Teirstein, P.S et al. (2011). Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: A time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation , 124, 1132–1137.
VII. Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP (2003) Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 101:3908–3914.
VIII. Drug Approval Package: Plavix/Clopidogrel bisulfate NDA 20839. [cited 2 Jun 2022]. Available.
IX. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP et al (2000) Identifcation and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891–896.
X. Stone, G.W.; Witzenbichler, B.; Weisz, G; et al.(2013). Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study. Lancet, 382, 614–623.
XI. Luo, M.; Li, J.; Xu, X.; Sun, X.; Sheng, W. (2012). ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: A meta-analysis. Thromb. Res. 129, 754–759.
XII. Jeong, Y.H.; Tantry, U.S.; Park, Y.; et al.(2012). Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention. Diabetes Care, 35, 2194–2197.
XIII. Best, P.J.M.; Lennon, R.; Ting, H.H.; Bell, M.R.; et al. (2002). The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J. Am. Coll. Cardiol., 39, 1113–1119.
XIV. Zhang, H.; Lau, W. C.; and Hollenberg, P. F.(2012). Formation of the thiol conjugates and active metabolite of clopidogrel by human liver microsomes. Mol. Pharmacol. 82:302–309.
XV. Angiolillo, D.J.; Bernardo, E.; Capodanno, D.; et al.(2010). Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J. Am. Coll. Cardiol, 55, 1139–114.
XVI. Bledsoe SL, Barr JC, Fitzgerald RT, Brown AT, et al (2006) Pravastatin and clopidogrel combined inhibit intimal hyperplasia in a rat carotid endarterectomy model. Vasc Endovascular Surg 40:4.
XVII. Bledsoe SL, Brown AT, Davis JA, et al. (2005). Efect of clopidogrel on platelet aggregation and intimal hyperplasia following carotid endarterectomy in the rat. Vascular 13:43–49.
XVIII. Hu. Honglin,; Batteux .Fred´ eric,; Chereau .Christiane,; Kavian. Niloufar ; et al. (2011). Clopidogrel protects from cell apoptosis and oxidative damage in a mouse model of renal ischaemia–reperfusion injury. J Pathol (2011) Published online in Wiley Online Library. DOI: 10.1002/path.2916.
XIX. Zahno .Anja; Bouitbir .Jamal; Maseneni .Swarna,;et al.(2013). Hepatocellular toxicity of clopidogrel: Mechanisms and risk factors. Free Radical Biology and Medicine 65; 208–216.
XX. Kumar S, Allen DA, Kieswich JE, et al. (2009).Dexamethasone ameliorates renal ischemia–reperfusion injury. J Am Soc Nephrol; 20: 2412–2425.